Compare Tango Therapeutics Inc. (TNGX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs ProShares Ultra Gold ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while ProShares Ultra Gold ETF trades at $45.54 (market cap $730.54M). The key difference: Tango Therapeutics Inc. is far larger — about 5.1× ProShares Ultra Gold ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| TNGX | UGL | |
|---|---|---|
Market Cap | $3.74B | $730.54M |
Volume | 3,438,781 | 4,212,910 |
Sector | Health | Leveraged / Inverse |
52-Week High | $32.90 | $85.62 |
52-Week Low | $7.50 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
UGL stock trades at $45.70, down 0.39% with bearish technical signals from moving averages. The stock faces pressure from broader market headwinds including rising Treasury yields and Federal Reserve policy uncertainty. Recent news highlights gold's struggle to maintain momentum despite intermittent safe-haven demand, with prices testing key support levels amid mixed economic data.
The outlook remains cautious with technical indicators suggesting continued near-term pressure. Investment opportunity exists for contrarian investors if gold regains its safe-haven appeal, though risks include persistent rate hike expectations and dollar strength. The stock's performance remains tightly linked to gold price movements and macroeconomic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
